Featured Stories

1:43 PM Jan 18, 2019
ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead candidate mirvetuximab soravtansine.

ImmunoGen was one of the first antibody-drug conjugate (ADC) companies when it was founded in 1981, and has...

1:22 PM Jan 18, 2019
Pharma falling off budget cliff

Three strong arms are lining up in Washington to take turns whacking the biopharma piñata. Divisions within the industry, a lack of new ideas, and resistance to change are making a bad situation worse for drug companies.

The first bat is synched to a clock that started ticking in 2018 when Congress passed a law that created a $126 billion budget hole...

BioCentury Management

Karen Bernstein, Ph.D., Co-Founder & Chairman

Karen is co-founder and chairman of BioCentury Inc. and was Editor-in-Chief from October 1992 to August 2015. She is a director at Ovid Therapeutics Inc., which is developing drugs for orphan diseases of the brain, and at Achaogen Inc., which markets Zemdri plazomicin to treat cUTI. She is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She serves on the board of overseers of Scripps Research. Karen holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards.

David Flores, Co-Founder, President & CEO 

David has devoted more than 25 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. David is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, David and BioCentury Co-Founder & Chairman Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury's ongoing contributions to the industry.

Thomas Carey, Vice President of Commercial Operations

Tom joined BioCentury in 2008 as Vice President of Commercial Operations. He has over 20 years of commercial experience in the pharmaceutical and biotech industry, serving in leadership roles in sales, marketing, product planning and business development. Tom was Senior Vice President of Sales and Marketing for Connetics, a specialty dermatology company now part of GlaxoSmithKline. He also was Vice President of Professional Sales as well as Vice President of Business Development at the OrthoNeutrogena division of Ortho-McNeil Pharmaceuticals, a Johnson & Johnson company. Tom's background also includes senior management positions at Roche Laboratories and Syntex Corp., which was acquired by Roche in 1994. He holds a bachelor's degree and an MBA from the University of California at Berkeley.

Simone Fishburn, Ph.D., Vice President and Executive Editor, BioCentury and BioCentury Innovations

Simone serves as Vice President and Executive Editor of BioCentury and BioCentury Innovations. She was previously Editor of BioCentury Innovations, and prior to that was a senior editor for SciBX: Science-Business eXchange, a joint publication between BioCentury and Nature Publishing Group. Simone also serves as an advisor on two university translational programs: the CTSI Catalyst program at the University of California San Francisco (UCSF) and the SPARK program at Stanford University. Prior to joining BioCentury in 2013, Simone spent nine years in preclinical drug development at Nektar Therapeutics, where she headed the pain program as director of translational research, and two years at Exponent Inc., where she assisted small and large biotechs on a range of scientific projects. Before she entered the industry, Simone spent eight years in academia, first as a post-doc at UCSF and then performing research at the Weizmann Institute of Science. Simone is also active in programs to advance women's careers; she is a Board member of Women In Bio and served as president from 2013-2014. She is a Fulbright scholar, and holds a Ph.D. in molecular pharmacology from the Weizmann, and an M.A. and B.A. in pharmacology from Cambridge University.

Bennet Weintraub, Vice President & Chief Financial Officer

Bennet Weintraub, Vice President & Chief Financial Officer Bennet, who joined BioCentury in 2004, has had an extensive career as a senior financial executive for development stage biotechnology and technology companies, having taken two companies public, and having completed numerous equity and debt financings and M&A transactions. He was CFO at InterMune, Valentis and Technology Modeling Associates, and held senior financial positions at Metra Biosystems and Advanced Polymer Systems. Bennet received his B.A. in Mathematical Economics from Pomona College and earned his MBA from Harvard University.

Eric Pierce, Publisher

Eric joined BioCentury in 1993 as its first Staff Writer, and became chief financial writer in 1996 when he originated "Ebb & Flow," BioCentury's weekly capital markets column. As Senior Editor for News, Eric managed BioCentury's news operations until 2004, when he joined the management team as Associate Publisher, and in 2007 was named Publisher. He holds an A.B. in Communication from Stanford University and completed graduate studies at the Mass Media Institute at Stanford, with an emphasis on broadcast journalism.

Susan Morgan, Director of Administration & Human Resources

Susan joined BioCentury in 2006, bringing with her extensive experience in the legal profession in New York. She holds a B.A. in Political Science from Fairfield University and a J.D. from Fordham University School of Law.